Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aethlon Medical Discloses Live Webcast of Today's BIOCOM Presentation
Monday 10/26/2009 5:00 AM ET - Pr Newswire
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed that today's presentation at the 4th Annual BIOCOM Investor Conference will be webcast live today. The presentation by Aethlon Chairman and CEO, James A. Joyce will begin at 2 p.m. pacific time and can be accessed on an audio-only basis at:
http://www.biocom.org/event/2009_Investor_Conference
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-
70 boardmarks.. up 40% in two days
beautiful intraday chart!
AEMD breakout HOY (.52)
AEMD breakout HOY (.52)
Thank god.. it's nice to see it in this range again!
Back up we go.. this could be a nice looking candle especially if we close HOD/HOY
Not just you.. maybe they're updating it/adding ESI information?
AEMD .0001 away from 52 week high :)
Board marks jumped 20% overnight to 61.
Welcome to all, please read the ibox even though it's a little out of date, and help us hold the gains from yesterday :)
Sheff, thanks for the additional awareness for AEMD.. I think we both agree it's a stock everyone should at least have on their radar.
With the HCV data in our sights (next Friday) it could very well be just the beginning, both near and long term, as you've alluded to.
Nice find, GWMAN.. and good memory :)
Here's to a continuation of the move today..
.47 x .48 EOD breakout coming, perhaps :)
.461 x .47
I wonder if they could use the hemopurifier to infuse something that would break up arterial plaque?
heh... getting ahead of msyelf, they should stick to getting things OUT of the blood first :)
What does the L2 look like going into the close?
Nice info, PK, thanks!
AEMD HOD on deck..
third leg up of the day on deck
Posted by: 2morrowsGains Date: Thursday, June 25, 2009 3:07:12 PM
In reply to: None Post # of 942
AEMD...Aethlon Medical's presentation notes...
Aethlon Medical presented at the Redchip Conference last week in Fort Lauderdale and IMO has more upside potential than all the other presenting companies put together. Only time will tell, but with a share price of $0.24 and a market cap of approx $15M, this company (stock) is DEFINITELY one for the watch list IMO!
Aethlon Medical has a product called the "Hemopurifier" that is now entering commercialization phase and it is surpassing the results of Vertex's (VRTX) HEP-C drug Telaprevir! (I believe Telaprevir is still a year or two away from being commercialized).
Vertex has a current market cap of $6B. Aethlon's market cap is approx $15M. Aethlon's CEO James Joyce calls it "an amazing phenomenon" regarding Aethlon's market value vs Vertex..."Hopefully that will adjust somewhat in the near future."
The comments and notes in this post are my opinion based on Aethlon Medical's Redchip (March & June) presentations. Here are the links to the presentations along with my notes...
June (Ft Lauderdale) Presentation w/ PowerPoint...
http://www.redchip.com/visibility/conferencePages/FTLauderdale2009/conferenceMain.asp?page=archive#
March (San Fransisco) Presentation...
http://www.redchip.com/visibility/conferencePages/SanFran2009/conferenceMain.asp?page=archive
"Aethlon Medical has a broad spectrum therapeutic device called the Hemopurifier. It's a multi-patented device that provides the ability to clear infectious viruses and amino suppressive proteins from circulation before the occurrence of cell and organ infection."
- "We believe the Hemopurifier is not just the leading broad spectrum candidate to treat bio-terror and pandemic threats, based on clinical data we think it's the only broad spectrum candidate to treat these threats."
- Now transitioning from a lengthy R&D phase and proof of principle phase, which included animal studies and human studies, into the commercialization phase!
- The technology has proven effective in treating Hepatitis C virus, HIV, and has demonstrated the ability to capture bio-terror threats and pandemic threats.
Aethlon believes they can dramatically increase cure rates in HEP-C, perhaps up to 90%!
- "We are establishing the industry to treat infectious disease and cancer with therapeutic filtration devices."
- Aethlon recently entered into an agreement to establish GMP manufacturing...
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1262531&highlight=
Expects product to start coming off the line towards the end of Q3 this year.
- Wants to establish Hemopurifier clinic sites in the U.S. and treatment centers India.
- "We are right now negotiating strategic partnerships related to expansive manufacturing, clinical partnerships, and development partnerships here in the U.S., and we are also involved in discussing partnerships with organizations that can provide future development of our technology, both as a portable device, and with applications into other fields."
- "At present our market cap is under $15M, but yet it's the only single therapy able to address bio-terror threats, HIV and Hepatitis C."
In the bio-terror and pandemic space, it's the leading broad spectrum candidate against these pathogens.
In HIV, it provides the solution to manage disease progression once patients become resistant to their drug regimens.
"In Hepatitis C, I believe it's going to soon be considered a leading adjunct candidate."
- The Hemoprifier is a single use disposable cartridge designed for use in conjunction with portable pumps and within the global infrastructure of dialysis machines already located in hospitals and clinics worldwide.
It acts as an artificial adjunct to the immune system, to inhibit progression of infectious and to improve treatment outcomes in cancer.
- In infectious disease it works to clear viruses before they can affect organs and cells by interrupting the replication process.
And the cartridge is also proven to remove amino suppressive proteins that are shed from the viruses that kill off immune cells.
- "We have also discovered that the cartridge has the ability to remove proteins that are secreted by tumors in cancer, that are known to kill off the immune system. So we have an amino therapeutic benefit in cancer therapy."
- "At this point in time, we're initializing commercialization overseas in practitioner driven markets. And something that's very crucial to point out, we are now entering our second decade of development. In terms of commercialization, our shareholders own 100% of the Hemopurifier. And this is very rare for a micro cap or small cap company. Usually by this phase there was a need or requirement to license out the technology, or to co-develop the technology which costs rights to the technology. So in this rare case, we actually own 100% of the technology as it moves toward marketplace."
- Aethlon Medical has only presented their information to a few analysts, the same analysts that cover Vertex and other players in the market. They have yet to come accros an analyst that was aware of the information. "But the analysts we have talked to concur, this could change the entire game and could be the cause to re-evaluate evaluations in the space."
- "While we're not known on Wall Street yet, patients know us. And I think that at the end of the day, value in our company is not going to be driven by bloggers, day traders, analysts and so on. It's going to be driven by patient demand and acceptance in the marketplace."
NBC report from March 2007...
AEMD DD starter originally posted by GWMAN on our AEMD board:
http://investorshub.advfn.com/boards/board.aspx?board_id=3094
2009 Calendar, Coverage, Slides, etc.
==> The Robins Group Coverage (Dec. 3, 2008)
Note: Earnings Estimate for Calendar 2009 is 0.14; based on calendar in coverage being overly optimistic, my personal hope is that AEMD will earn 0.00-0.05 for calendar 2009
http://www.therobinsgroup.biz/files/12_03_08_AEMD_IC.pdf
==> Latest Letter to Shareholders (Feb. 24, 2009)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1259383&highlight=
==> Video of RedChip Conference Presentation, accompanying slides and follow-up RedChipTV interview (Mar. 24, 2009)
http://www.redchip.com/visibility/conferencePages/SanFran2009/conferenceMain.asp?page=archive
==> Latest CEO Webcast (Mar. 5, 2009)
http://www.ceocast.com/(1t5vjl331gce04nvkcnow433)/company.aspx?id=1049
==> Current Chart TA
http://www.stockta.com/cgi-bin/analysis.pl?symb=AEMD&num1=13&cobrand=&mode=stock
==> Updated 2009 Calendar
**Note that I will be bolding the milestones that have been acheived as I update this periodically.
March:
1. Results from HIV study (DONE)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1265082&highlight=
2. Results from 30-day HCV study (Semi-DONE)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1269792&highlight=
April:
1. Notification on potential award from Bill and Melinda Gates Foundation (DONE)
Note: AEMD did not get this Round 2 grant, largely because the objective identified in the grant application was acheived by the company in India before the Gates Foundation even made a decision on whether or not to award AEMD a grant. The Gates Foundation encouraged AEMD to refine the application and resubmit it for Round 3.
May/June:
1. Notification on potential 5-year contract award from BARDA/fed gov
2. Release of Annual Report
3. Completion of GMP Manufacturing and Quality Systems to allow commerical export
Other 2009 Milestones (targeted month unknown):
1. Announcment of agreement to treat Dengue Fever in India
Note recent addition to team of Director of Business Development from India, http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1248744&highlight=
2. Establish data-supported HIV strategy for Undetectable Viral Load (DONE)
http://finance.yahoo.com/news/Aethlon-Medical-Discloses-New-prnews-15132368.html?.v=1
3. Close on strategic partnership(s) and negotiate strategic investment
4. Announcment on the planned contract production partner referenced in the investment firm write-up (DONE)
http://phx.corporate-ir.net/phoenix.zhtml?c=95588&p=irol-newsArticle&ID=1262531&highlight=
5. Initiation of commerical production for sale of product in India
6. Starting of clinical trials in U.S. involving 10-patient safety study mimicing what has already been conducted in India (Described by CEO as near-term objective at RedChip Conference)
7. Define regulatory and commericalization plan for European Union
8. Complete currently ongoing in-vitro Cytomegalovirus study
9. Announce research plan and progress to concetnrate and subsequently identify new viruses underlying specific diseases and identify biomarkers that can be targetes for drug intervention.
10. Announce research progress to advance adjunct cancer treatment possibilities. (Creation of wholly owned subsidiary Exosome Sciences - DONE)
50 boardmarks for the first time ever during my tenure as the moderator.
I'm going to update the Ibox this weekend sometime. GWMAN, if you get a chance feel free to change whatever you want as well.
Welcome, Sheff! It's reassuring to know you're a fan of the company as well given your professional experience.
What do you think about the Exosome news today?
hmmmmm
www.exosomesciences.com is already taken..
I would love to see a website for ESI
They mentioned potentially staffing ESI with their own management team, etc. I think a 43B market opportunity is with the special focus of a separate company, especially given JJ's statement about wanting to be a signficant player in this up and coming industry.
Additionally, it seems to give them the opportunity for AEMD and ESI to partner with different companies within their respective industries and with fewer contractual conflicts.
Congrats again longs.. this one is finally about to go for real.
Me too, this is huge!
"ESI allows us to leverage the previously unrecognized value of our non-infectious disease research into a new asset that positions us to be an important participant in the emerging exosome industry. We also maintain the option of installing an independent management team at ESI and if appropriate in the future, may spin out part or all of ESI as a means to achieve fuller valuation for Aethlon Medical (AEMD:$0.36,00$0.04,0012.50%) shareholders," concluded Joyce.
There may not be a lot of deaths, but there will be many infected..
http://www.foxnews.com/story/0,2933,568607,00.html?loomia_ow=t0:s0:a16:g2:r3:c0.034016:b28424979:z10
I wonder what can we do if the vaccine is too late?
I'm in Chicago this week and heard about this on the local AM radio..
http://www.chicagotribune.com/news/chi-ap-il-schoolclosed-illn,0,7268985.story
Volume 2M... very, very nice
GWMAN, do you think are we to assume this will be the complete package of HCV results including the stuff we're still waiting on, or just what they've already disclosed and/or hinted at publicly?
You were saying? ;)
I'm looking to add another 8k or so to my position.. sideways the rest of the day or a further pullback before the HCV run up?
I alerted this board about a month or two ago at .22ish and AEMD was officially 'Sheff Station Certified' as of then.
Up 50.88% so far today, with HCV news expected in the near future.
WOOO congrats fellow longs, long term UP trend now, boys.
Count me in, I'll be making the trip as well.. our time is coming
You may be a rich mofo but sometimes no one can understand your posts, Lion Taki ;)
Melbourne-Boston sister city relationship... Eric wasn't making this crap up...
http://www.melbourne.vic.gov.au/info.cfm?top=161&pg=1646
didn't even know that was a real kind of relationship haha..
I wonder if there is significance to them mentioning Boston, specifically, as the sister city to melbourne. They could have mentioned Sydney as the 'New York of Australia', but perhaps that is a given..
OR maybe something is brewing in Beantown besides Sam Adams Lager and a Red Sox world series championship...??